Gilead Sciences beats quarterly estimates behind strong HIV drug sales
Gilead Sciences surpassed quarterly expectations today driven by strong sales of its HIV drugs. The firm issued a cautious outlook for the 2026 fiscal year.
Insights:
Gilead Sciences, Inc. reported fourth-quarter financial results on Tuesday that modestly exceeded Wall Street expectations for both revenue and earnings. Despite the beat, the company issued a conservative 2026 guidance range that sits at the lower end of analyst forecasts. The update, released on February 10, 2026, reflects a shift in near-term expectations as the company navigates a changing regulatory landscape in the US 
US.
US.For the fourth quarter, the company posted revenue of $7.9 billion and adjusted earnings per share (EPS) of $1.86. These figures were slightly above the estimates previously set by Wall Street. However, management lowered the near-term revenue and earnings outlook, citing specific external pressures that are expected to impact growth in the coming year.
